These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 33819006

  • 1. Co-Delivery of Curcumin and Capsaicin by Dual-Targeting Liposomes for Inhibition of aHSC-Induced Drug Resistance and Metastasis.
    Qi C, Wang D, Gong X, Zhou Q, Yue X, Li C, Li Z, Tian G, Zhang B, Wang Q, Wei X, Wu J.
    ACS Appl Mater Interfaces; 2021 Apr 14; 13(14):16019-16035. PubMed ID: 33819006
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. GA&HA-Modified Liposomes for Co-Delivery of Aprepitant and Curcumin to Inhibit Drug-Resistance and Metastasis of Hepatocellular Carcinoma.
    Li Y, Wu J, Lu Q, Liu X, Wen J, Qi X, Liu J, Lian B, Zhang B, Sun H, Tian G.
    Int J Nanomedicine; 2022 Apr 14; 17():2559-2575. PubMed ID: 35698562
    [Abstract] [Full Text] [Related]

  • 4. Dual-Ligand-Modified Liposomes Co-Loaded with Anti-Angiogenic and Chemotherapeutic Drugs for Inhibiting Tumor Angiogenesis and Metastasis.
    Wang F, Li Y, Jiang H, Li C, Li Z, Qi C, Li Z, Gao Z, Zhang B, Wu J.
    Int J Nanomedicine; 2021 Apr 14; 16():4001-4016. PubMed ID: 34135585
    [Abstract] [Full Text] [Related]

  • 5. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
    Cheng Y, Zhao P, Wu S, Yang T, Chen Y, Zhang X, He C, Zheng C, Li K, Ma X, Xiang G.
    Int J Pharm; 2018 Jul 10; 545(1-2):261-273. PubMed ID: 29730175
    [Abstract] [Full Text] [Related]

  • 6. Antitumor activities of novel glycyrrhetinic acid-modified curcumin-loaded cationic liposomes in vitro and in H22 tumor-bearing mice.
    Chang M, Wu M, Li H.
    Drug Deliv; 2018 Nov 10; 25(1):1984-1995. PubMed ID: 30499350
    [Abstract] [Full Text] [Related]

  • 7. Curcumin and berberine co-loaded liposomes for anti-hepatocellular carcinoma therapy by blocking the cross-talk between hepatic stellate cells and tumor cells.
    Wu J, Qi C, Wang H, Wang Q, Sun J, Dong J, Yu G, Gao Z, Zhang B, Tian G.
    Front Pharmacol; 2022 Nov 10; 13():961788. PubMed ID: 36188590
    [Abstract] [Full Text] [Related]

  • 8. [Establishment of a novel co-cultured liver cancer model based on tumor microenvironment].
    Qi CP, Wang D, Wei XH, Zhang B, Wu JL.
    Zhonghua Zhong Liu Za Zhi; 2023 May 23; 45(5):389-395. PubMed ID: 37188623
    [Abstract] [Full Text] [Related]

  • 9. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
    Huang S, Ren D, Wu X, Li M, Yu X, Nie X, Wang Y, Wang Y.
    Curr Top Med Chem; 2020 May 23; 20(27):2493-2505. PubMed ID: 32703132
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor therapy of glycyrrhetinic acid targeted liposome co-delivery of doxorubicin and berberine for hepatocellular carcinoma.
    Xu N, Wu J, Wang W, Sun S, Sun M, Bian Y, Zhang H, Liu S, Yu G.
    Drug Deliv Transl Res; 2024 Sep 23; 14(9):2386-2402. PubMed ID: 38236508
    [Abstract] [Full Text] [Related]

  • 11. Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects.
    Jiang H, Li ZP, Tian GX, Pan RY, Xu CM, Zhang B, Wu JL.
    Int J Nanomedicine; 2019 Sep 23; 14():1789-1804. PubMed ID: 30880980
    [Abstract] [Full Text] [Related]

  • 12. Curcumin-loaded liposomes with the hepatic and lysosomal dual-targeted effects for therapy of hepatocellular carcinoma.
    Wang Y, Ding R, Zhang Z, Zhong C, Wang J, Wang M.
    Int J Pharm; 2021 Jun 01; 602():120628. PubMed ID: 33892061
    [Abstract] [Full Text] [Related]

  • 13. CREKA-modified liposomes target activated hepatic stellate cells to alleviate liver fibrosis by inhibiting collagen synthesis and angiogenesis.
    Li R, Zhang J, Liu Q, Tang Q, Jia Q, Xiong Y, He J, Li Y.
    Acta Biomater; 2023 Sep 15; 168():484-496. PubMed ID: 37392933
    [Abstract] [Full Text] [Related]

  • 14. Development of 11-DGA-3-O-Gal-Modified Cantharidin Liposomes for Treatment of Hepatocellular Carcinoma.
    Zhou L, Zou M, Zhu K, Ning S, Xia X.
    Molecules; 2019 Aug 24; 24(17):. PubMed ID: 31450608
    [Abstract] [Full Text] [Related]

  • 15. Development of Salvianolic acid B-Tanshinone II A-Glycyrrhetinic acid compound liposomes: formulation optimization and its effects on proliferation of hepatic stellate cells.
    Lin J, Wang X, Wu Q, Dai J, Guan H, Cao W, He L, Wang Y.
    Int J Pharm; 2014 Feb 28; 462(1-2):11-8. PubMed ID: 24374609
    [Abstract] [Full Text] [Related]

  • 16. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid.
    Li J, Xu H, Ke X, Tian J.
    J Drug Target; 2012 Jun 28; 20(5):467-73. PubMed ID: 22577855
    [Abstract] [Full Text] [Related]

  • 17. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
    Qiu M, Wang J, Bai J, Li X, Tian C, Liu Z, Zheng C, Clark AR, Cheng X, Liao X, Wu S, Lee RJ, Zhou X.
    Mol Pharm; 2023 Apr 03; 20(4):1951-1963. PubMed ID: 36952242
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic Response of Multifunctional Lipid and Micelle Formulation in Hepatocellular Carcinoma.
    Wu J, Wang F, Dong J, Zhang S, Li N, Zhao H, Liu X, Gao Z, Zhang B, Tian G.
    ACS Appl Mater Interfaces; 2022 Oct 12; 14(40):45110-45123. PubMed ID: 36167351
    [Abstract] [Full Text] [Related]

  • 19. Novel Chinese Angelica Polysaccharide Biomimetic Nanomedicine to Curcumin Delivery for Hepatocellular Carcinoma Treatment and Immunomodulatory Effect.
    Guo C, Hou X, Liu Y, Zhang Y, Xu H, Zhao F, Chen D.
    Phytomedicine; 2021 Jan 12; 80():153356. PubMed ID: 33039729
    [Abstract] [Full Text] [Related]

  • 20. 18-GA-Suc Modified Liposome Loading Cantharidin for Augmenting Hepatic Specificity: Preparation, Characterization, Antitumor Effects, and Liver-Targeting Efficiency.
    Zhu K, Zhou L, Zou M, Ning S, Liu S, Zhou Y, Du K, Zhang X, Xia X.
    J Pharm Sci; 2020 Jun 12; 109(6):2038-2047. PubMed ID: 32173319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.